The Phase I/II Trials Collaborative for Children, Adolescents, and Young Adults at UH Rainbow Babies & Children's Hospital and the Case Comprehensive Cancer Center
Innovative pediatric developmental therapeutic programs are critical to the identification of novel agents that offer the prospect of more effective and less toxic therapies for pediatric cancers.
The pediatric phase I/II trials collaborative for children, adolescents, and young adults at Rainbow Babies & Children's Hospital (RB&C) and the Case Comprehensive Cancer Center (Case CCC) is a unique partnership among the pediatric oncology team at RB&C, the medical oncology team at Case CCC, and translational scientists at Case Western Reserve University (CWRU). The pediatric phase I/II program has been designed to leverage the outstanding science and clinical research expertise of the CWRU and the adult Developmental Therapeutics (DVL) Program at Case CCC and extend the established opportunities and successes in the care of young adults with relapsed/refractory cancer to children and adolescents.
The organization of the pediatric phase I/II program draws from both the existing infrastructure of the adult DVL Program at the Case CCC as well as the existing infrastructure that supports phase II/III pediatric oncology trials at RB&C. Over the next 5 years, we anticipate significant growth in our program as a result of increased trials (consortia, industry, investigator-initiated) as well as the formation of a NE Ohio pediatric phase I/II network consisting of five regional children's hospitals. Central to the growth and success of the pediatric DVL Program is consistent financial support such as that provided in this ALSF Infrastructure Award. Together, we can transform scientific discovery into clinical success for children, adolescents, and young adults with cancer.